Lord, Abbett & Co’s Revolution Medicines RVMD Stock Holding History

Lord, Abbett & Co’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$109M	Sell	533,183 -256,058	-32%	-$50.8M	0.33%	81
2026 Q2	$148M	Buy	789,241 +655,008	+488%	+$95.7M	0.42%	59
2026 Q1	$13.1M	Sell	134,233 -265,251	-66%	-$26.8M	0.04%	327
2025 Q4	$31.8M	Buy	+399,484	New	+$26.2M	0.1%	204
2025 Q2	–	Sell	-367,630	Closed	-$13M	–	572
2025 Q1	$13M	Sell	367,630 -1,611,090	-81%	-$65.4M	0.05%	336
2024 Q4	$86.5M	Buy	1,978,720 +146,699	+8%	+$7.4M	0.27%	101
2024 Q3	$83.1M	Buy	+1,832,021	New	+$79.8M	0.26%	113
2020 Q3	–	Sell	-97,987	Closed	-$3.09M	–	675
2020 Q2	$3.09M	Sell	97,987 -52,807	-35%	-$1.66M	0.01%	603
2020 Q1	$3.3M	Buy	+150,794	New	+$4.17M	0.01%	576

Other funds holding RVMD

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Lord, Abbett & Co's RVMD Position: Q3 2026 in Review

Lord, Abbett & Co reduced its Revolution Medicines (RVMD) stake by 32% in Q3 2026, selling an estimated $50.8M and leaving 533,183 shares worth $109M. The position accounts for 0.33% of the portfolio, ranked #81.

Lord, Abbett & Co first reported a position in RVMD in Q1 2020 and has held it in 9 quarters since. The position peaked at $148M in Q2 2026. 577 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

Lord, Abbett & Co held 533,183 shares of Revolution Medicines worth $109M as of Q3 2026.
Lord, Abbett & Co sold 256,058 Revolution Medicines shares in Q3 2026, an estimated $50.8M.
Revolution Medicines made up 0.33% of Lord, Abbett & Co's portfolio in Q3 2026, its #81 holding.
Lord, Abbett & Co first reported a position in Revolution Medicines in Q1 2020 and has held it in 9 quarters since.
Lord, Abbett & Co's Revolution Medicines position peaked at $148M in Q2 2026.
577 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.